Lexaria Bioscience Corp. (LEXX)
NASDAQ: LEXX · Real-Time Price · USD
0.8661
+0.0861 (11.04%)
At close: Apr 1, 2026, 4:00 PM EDT
0.9000
+0.0339 (3.91%)
After-hours: Apr 1, 2026, 7:47 PM EDT
Lexaria Bioscience Employees
Lexaria Bioscience had 7 employees as of August 31, 2025. The number of employees did not change compared to the previous year.
Employees
7
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
$74,571
Profits / Employee
-$1,541,878
Market Cap
21.56M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Aug 31, 2025 | 7 | 0 | - |
| Aug 31, 2024 | 7 | 2 | 40.00% |
| Aug 31, 2023 | 5 | -2 | -28.57% |
| Aug 31, 2022 | 7 | 1 | 16.67% |
| Aug 31, 2021 | 6 | 2 | 50.00% |
| Aug 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Senti Biosciences | 34 |
| Curis | 34 |
| Passage Bio | 24 |
| Tempest Therapeutics | 21 |
| Outlook Therapeutics | 17 |
| Skye Bioscience | 12 |
| VYNE Therapeutics | 10 |
| Neuphoria Therapeutics | 8 |
LEXX News
- 18 hours ago - Lexaria to Begin New Human Clinical Study in GLP-1 - TheNewswire
- 6 days ago - Lexaria's Robust Patent Portfolio Continues to Grow - Accesswire
- 8 days ago - Lexaria's Oral GLP-1 Drug Strategy Validated by Industry - TheNewswire
- 4 weeks ago - Lexaria Announces New R&D Plans for 2026 - Accesswire
- 7 weeks ago - Lexaria Announces Positive Final Results From Human Pilot Study #5 - Accesswire
- 2 months ago - Lexaria Awarded Six Additional Patents - Accesswire
- 2 months ago - Lexaria Releases Annual Letter from the CEO - Accesswire
- 3 months ago - Lexaria Releases Additional Results from its Successful Phase 1b Study GLP-1-H24-4 - Accesswire